Last $69.92 USD
Change Today +0.13 / 0.19%
Volume 49.0K
ICUI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

icu medical inc (ICUI) Snapshot

Open
$70.06
Previous Close
$69.79
Day High
$70.91
Day Low
$69.15
52 Week High
10/22/14 - $70.98
52 Week Low
05/5/14 - $54.00
Market Cap
1.1B
Average Volume 10 Days
135.5K
EPS TTM
$2.46
Shares Outstanding
15.3M
EX-Date
--
P/E TM
28.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ICU MEDICAL INC (ICUI)

icu medical inc (ICUI) Related Businessweek News

No Related Businessweek News Found

icu medical inc (ICUI) Details

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, oncology, and critical care applications. It operates in three segments: Infusion Therapy, Critical Care, and Oncology. The company’s product line includes needlefree infusion connectors, custom infusion systems, catheters and hemodynamic monitoring systems, closed system transfer devices, and automated compounders for handling hazardous drugs. Its products enhance patient outcomes by preventing bloodstream infections, and protecting healthcare workers and patients from exposure to infectious diseases or hazardous drugs. The company offers I.V. therapy lines consisting of a tube running from a bottle or plastic bag containing an I.V. solution to a catheter inserted in a patient’s vein for use in hospitals and ambulatory clinics; and Clave product, a needlefree infusion connection device, which is used with conventional peripheral or central vascular access systems for venous and arterial applications. It also provides critical care products that monitor vital signs and specific physiological functions of key organ systems, including disposable pressure-sensing devices, blood sampling systems, minimally invasive monitoring sensors, catheters, and angiography kits for various purposes. In addition, the company provides a line of oncology products, including ChemoLock and ChemoClave closed system transfer device and components, including Genie closed vial access device and Spiros closed male luer; custom preparation and administration sets and accessories; and Diana hazardous drug compounding system. Further, it offers Tego needlefree hemodialysis connectors and Lopez enteral valves. ICU Medical, Inc. sells its products to medical product manufacturers, independent distributors, and directly to end users. The company was founded in 1984 and is headquartered in San Clemente, California.

2,269 Employees
Last Reported Date: 02/21/14
Founded in 1984

icu medical inc (ICUI) Top Compensated Officers

Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $406.6K
Vice President of Operations
Total Annual Compensation: $399.4K
Vice President of Product Development
Total Annual Compensation: $315.0K
Compensation as of Fiscal Year 2013.

icu medical inc (ICUI) Key Developments

ICU Medical Announces Study Results of ChemoClave Closed System Transfer Device and MicroClave Neutral Displacement Connector

ICU Medical, Inc. announced that a new study presented this week at the 38(th) Annual Association of Pediatric Hematology/Oncology Nurses (APHON) Conference in Portland, OR showed that the company's ChemoClave(R) closed system transfer device (CSTD) contributed to a significant reduction in chemotherapy spills and exposures, while a switch to ICU Medical's MicroClave(R) Clear neutral displacement connector from the MaxPlus(R) positive pressure connector (CareFusion Corporation, San Diego, CA) contributed to a reduction in central line-associated bloodstream infections (CLABSI). To test the ChemoClave system's ability to limit chemotherapy spills and exposures, clinicians in the pediatric oncology unit recorded the number of times they entered a patient's line over a 24-hour period and documented any leaks at the connection site both before and after ChemoClave implementation. Before implementation of the ChemoClave system, clinicians recorded a total of 23 potential exposures out of the 24 times a patient's line was entered. Following implementation, use of the ChemoClave system was associated with 0 potential exposures out of the 47 times a patient's line was entered in a 24-hour period.

ICU Medical, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Year 2014

ICU Medical, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2014. for the quarter, the company reported net sales of $78,555,000 against $78,537,000 a year ago. Total revenue was $78,677,000 against $78,661,000 a year ago. Income from operations was $8,698,000 against $10,950,000 a year ago. Income before income taxes was $8,905,000 against $11,162,000 a year ago. Net income was $5,878,000 against $7,367,000 a year ago. Diluted earnings per share were $0.38 against $0.48 a year ago. Adjusted EBITDA was $16,292,000 against $17,709,000 a year ago. The decline was primarily due to increased R&D expenditures and a slight decrease in gross margin. Adjusted diluted earnings per share were $0.51 against $0.58 a year ago. Additionally, the company generated operating cash flow of $16.6 million for the second quarter of 2014. GAAP net income was $6 million or $0.38 per diluted share, as compared to $7 million or $0.48 per diluted share last year. The decrease was primarily due to a noncash-based stock compensation expense and increased R&D. For the six months, the company reported net sales of $151,668,000 against $152,710,000 a year ago. Total revenue was $151,907,000 against $152,960,000 a year ago. Income from operations was $18,575,000 against $22,975,000 a year ago. Income before income taxes was $18,992,000 against $23,355,000 a year ago. Net income was $12,535,000 against $16,052,000 a year ago. Diluted earnings per share were $0.81 against $1.06 a year ago. Adjusted EBITDA was $33,117,000 against $36,326,000 a year ago. Net cash provided by operating activities was $29,275,000 against $25,956,000 a year ago. Purchases of property and equipment was $12,729,000 against $11,781,000 a year ago. Intangible asset additions was $377,000 against $633,000 a year ago. Adjusted diluted earnings per share were $1.06 against $1.27 a year ago. For the year 2014, the company is raising adjusted EBITDA, adjusted EPS and GAAP EPS guidance ranges. GAAP diluted earnings per share is increased to a range of $1.30 to $1.50 compared to the previous range of $1.15 to $1.45. Adjusted diluted earnings per share is in the range of $1.95 to $2.15, and adjusted EBITDA range is increased to $63 million to $68 million compared to the previous range $58 million to $65 million. GAAP net income is to be in the range between from $20,148,000 to $23,183,000. Depreciation and amortization expense is to be in the range between from $19,998,000 to $19,998,000. Amortization expense per share is to be $0.60. Gross margins to be approximately 49%. Tax rate to be approximately 34%. CapEx spend to be $16 million to $19 million this year and to start declining in 2015.

ICU Medical, Inc. to Report Q2, 2014 Results on Aug 11, 2014

ICU Medical, Inc. announced that they will report Q2, 2014 results at 4:00 PM, US Eastern Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICUI:US $69.92 USD +0.13

ICUI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $50.96 USD -0.18
Exactech Inc $21.36 USD -0.07
Merit Medical Systems Inc $14.89 USD +2.01
Tornier NV $23.59 USD +0.20
Wright Medical Group Inc $31.86 USD +0.37
View Industry Companies
 

Industry Analysis

ICUI

Industry Average

Valuation ICUI Industry Range
Price/Earnings 29.2x
Price/Sales 3.4x
Price/Book 2.2x
Price/Cash Flow 28.9x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICU MEDICAL INC, please visit www.icumed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.